Marked improvement in HbA1c following introduction of biosimilar insulin to treatment regimen of children and youth with type 1 diabetes in Mali: A randomised controlled trial
Diabetic Medicine · 2025
DOI: 10.1111/dme.70007 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetic Medicine, 2025. Verfasst von Stéphane Besançon und 12 weiteren Autor:innen. Beteiligte Einrichtung: Santé Diabète, Bamako, Mali. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Glycated Hemoglobin, Biosimilar Pharmaceuticals, Hypoglycemic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Leona M. and Harry B. Helmsley Charitable Trust.
Themen: Diabetes mellitus, Kinderkrankenpflege
Abstract (Originalsprache)
Aims
Evidence on outcomes of treating type 1 diabetes (T1D) with long‐acting basal insulins in low‐resourced settings is lacking. This study aimed to evaluate the impact of switching children and youth with T1D in the low‐income country of Mali from human insulin via syringe to long‐acting biosimilar insulin glargine delivered by reusable pens combined with short‐acting insulin via syringe.
Methods
A two‐group parallel design randomised trial was conducted enrolling 260 youth aged
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Santé Diabète, Bamako, Mali.
- Life for a Child Program, Diabetes Australia, Glebe, New South Wales, Australia.
- Hôpital du Mali, Yirimadio, Bamako, Mali.
- Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead, Westmead, New South Wales, Australia.
- Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
- Pediatric Clinic, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg.
ORCID-Profile: David Beran
Förderung
- Leona M. and Harry B. Helmsley Charitable Trust
Zitieren
APA
Besançon, S., Haynes, A., Togo, A. D., Sandy, J. L., Maniam, J., Sidibe, A. T., Djéneba, S., de Beaufort, C., Perolini, M. C., Gastaldi, G., Beran, D., Eigenmann, C., & Ogle, G. D. (2025). Marked improvement in HbA1c following introduction of biosimilar insulin to treatment regimen of children and youth with type 1 diabetes in Mali: A randomised controlled trial. Diabetic Medicine. https://doi.org/10.1111/dme.70007
Vancouver
Besançon S, Haynes A, Togo AD, Sandy JL, Maniam J, Sidibe AT, et al. Marked improvement in HbA1c following introduction of biosimilar insulin to treatment regimen of children and youth with type 1 diabetes in Mali: A randomised controlled trial. Diabetic Medicine. 2025. doi:10.1111/dme.70007
BibTeX
@article{Besanon2025,
author = {Besançon, Stéphane and Haynes, Aveni and Togo, Amagara Domon and Sandy, Jessica Lynn and Maniam, Jayanthi and Sidibe, Asa Traoré and Djéneba, Sylla and de Beaufort, Carine and Perolini, Montserrat Castellsague and Gastaldi, Giacomo and Beran, David and Eigenmann, Cecile and Ogle, Graham David},
title = {Marked improvement in HbA1c following introduction of biosimilar insulin to treatment regimen of children and youth with type 1 diabetes in Mali: A randomised controlled trial},
journal = {Diabetic Medicine},
year = {2025},
doi = {10.1111/dme.70007}
}
EUVIMED